Evaluate the cardiovascular risk profile of nicotine replacement therapy

This matched cohort study will compare the cardiovascular disease (CVD) event rate in smokers undertaking unaided smoking cessation attempts (the non-exposed group) with the event rate in smokers attempting smoking cessation assisted by pharmacological interventions – by nicotine replacement therapy (NRT) (as any, or a combination, of: nasal spray, transdermal patches, inhaler or gum and tablets) or other pharmacological smoking cessation aids (e.g. bupropion [Zyban®] and varenicline [Champix®]) – in a representative UK primary care population.

Lead Investigator:
Professor David Price
Research Team:
Dr Mike Thomas
Professor Amanda Lee
Dr Frances Elender
Julie von Ziegenweidt
Muzammil Ali
Martha Joseph
Alison Chisholm

Status: Active Study
Support: Respiratory Effectiveness Group
Registration: ENCePP 4241
Documents and Publications:
Final Publications
Additional Material

Leave a Reply

Your email address will not be published. Required fields are marked *